BANCOR
Bancor today announced its first NFT collection, “DEXLoverz” Condom NFTs, to highlight Impermanent Loss Protection on Valentine’s Day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220214005054/en/
Minted on Polygon, the collection features 1,500 Condom NFTs with varying levels of rare attributes. Recipients of DEXLoverz include active users in Bancor's DAO, as well as users who suffered extreme cases of Impermanent Loss on popular AMMs like Uniswap, Sushiswap, Balancer. The condom NFTs, designed by DIGITALAX , will be airdropped on Valentine’s Day as a reminder to urge DeFi liquidity providers to protect the tokens they love and practice Safe DEX.
Bancor has been developing innovative liquidity products since its launch: Bancor V1 introduced the first automated market maker (AMM) in 2017, while the current Bancor V2.1 addresses Impermanent Loss, a common issue in DeFi plaguing users who deposit their assets in AMM liquidity pools. When Impermanent Loss occurs, it can cause the cumulative value of the pooled tokens to be worth less than holding the assets in the user’s wallet. Roughly 50% of users suffer negative returns due to Impermanent Loss, a recent study found.
Bancor's "Safe Staking" solution offers single-sided liquidity and Impermanent Loss protection, allowing users to earn higher profits with lower risk. In 2021, LPs earned over $250 million on Bancor in tokens like ETH, WBTC, LINK, SNX and more, with APRs reaching 40-60%.
Nate Hindman, Bancor’s Head of Growth, said: "Staking in DeFi liquidity pools is not a passive income strategy. It is a risky trading strategy that can lead to heavy losses. Bancor is the only DEX offering token holders and DAOs real passive income through its Impermanent Loss protection model. The DEXLoverz collection aims to bring awareness of Impermanent Loss to DeFi users and remind them there’s a safe way to stake at Bancor.”
DEXLoverz holders will get access to exclusive benefits, events and utilities on Bancor in the future. Initially, holders can stake their DEXLoverz on DIGITALAX to earn rewards. To celebrate the drop, Bancor is giving away 10 DEXLoverz to 10 winners – visit Bancor’s blog for more details.
Bancor’s new proposed protocol update, Bancor 3 , will make Impermanent Loss Protection even easier and cheaper to use, so users can earn more while doing less.
Practice Safe DEX now. Check your Impermanent Loss at IL.WTF and stake safely on Bancor .
Helpful Links
About Bancor
Bancor is the only decentralized staking protocol that allows you to earn on your favorite tokens with single-asset exposure and 100% protection from Impermanent Loss. Bancor generates millions in fees per month for depositors, offering up to 60% APR on tokens like ETH, WBTC, LINK & more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom